title: Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures.
abstract: OBJECTIVE
  We sought to evaluate immediate and late outcomes after stenting for left main coronary artery (LMCA) stenosis.
  
  
  BACKGROUND
  Conventional percutaneous transluminal coronary angioplasty (PTCA), for which coronary artery bypass grafting (CABG) has been the gold standard therapy for years, has yielded poor results in unprotected LMCA lesions. The development of coronary stents, together with their dramatic patency improvement provided by new antiplatelet regimens and their validation against restenosis, warrants a reappraisal of angioplasty in LMCA stenosis.
  
  
  METHODS
  From January 1993 to September 1998, 140 consecutive unselected patients with unprotected LMCA stenosis underwent elective stenting. Group I included 47 high-CABG-risk patients, and group II included 93 low-CABG-risk patients. Ticlopidine without aspirin was routinely started at least 72 h before the procedure and continued for one month. Patients were reevaluated monthly. A follow-up angiography was requested after six months.
  
  
  RESULTS
  The procedure success rate was 100%. One-month mortality was 9% (4/47) in group I and 0% in group II. A follow-up angiography was obtained in 82% of cases, and target lesion revascularization was required in 17.4%. One-year actuarial survival was 89% in the first 29 group I patients and 97.5% in the first 63 group II patients.
  
  
  CONCLUSIONS
  Stenting of unprotected LMCA stenosis provided excellent immediate results, particularly in good CABG candidates. Medium-term results were good, with a restenosis rate of 23%, similar to that seen after stenting at other coronary sites. Stenting deserves to be considered a safe and effective alternative to CABG in institutions performing large numbers of PTCAs.
authors.affiliation: Cardiology Department, Beauregard Private Hospital Center, Marseille, France. msilvestri_cuecv@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Silvestri
authors.forename: P
authors.initials: P
authors.lastname: Barragan
authors.forename: J
authors.initials: J
authors.lastname: Sainsous
authors.forename: G
authors.initials: G
authors.lastname: Bayet
authors.forename: J B
authors.initials: JB
authors.lastname: Simeoni
authors.forename: P O
authors.initials: PO
authors.lastname: Roquebert
authors.forename: G
authors.initials: G
authors.lastname: Macaluso
authors.forename: J L
authors.initials: JL
authors.lastname: Bouvier
authors.forename: B
authors.initials: B
authors.lastname: Comet
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D011292:Premedication; D015607:Stents; D015996:Survival Rate; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine